These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 8094034)

  • 1. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
    Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D; Matin A; Xia W; Sorgi F; Huang L; Hung MC
    Oncogene; 1995 Oct; 11(7):1383-8. PubMed ID: 7478560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
    Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y; Yu D; Xia W; Hung MC
    Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
    Yu D; Shi D; Scanlon M; Hung MC
    Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products.
    Yu D; Hamada J; Zhang H; Nicolson GL; Hung MC
    Oncogene; 1992 Nov; 7(11):2263-70. PubMed ID: 1359495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of intratracheal lung cancer development by systemic delivery of E1A.
    Chang JY; Xia W; Shao R; Hung MC
    Oncogene; 1996 Oct; 13(7):1405-12. PubMed ID: 8875978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene.
    Lin YC; Peng JM; Wang WB
    Oncogene; 2000 May; 19(22):2704-13. PubMed ID: 10851070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene.
    Kao MC; Liu GY; Chuang TC; Lin YS; Wuu JA; Law SL
    Oncogene; 1998 Jan; 16(4):547-54. PubMed ID: 9484845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
    Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
    Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.
    Wiechen K; Karaaslan S; Turzynski A; Dietel M
    Br J Cancer; 1999 Nov; 81(5):790-5. PubMed ID: 10555747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism.
    Frisch SM; Dolter KE
    Cancer Res; 1995 Dec; 55(23):5551-5. PubMed ID: 7585633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu.
    Chen H; Yu D; Chinnadurai G; Karunagaran D; Hung MC
    Oncogene; 1997 Apr; 14(16):1965-71. PubMed ID: 9150363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
    Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC
    Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H; Qin H; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
    Langton BC; Crenshaw MC; Chao LA; Stuart SG; Akita RW; Jackson JE
    Cancer Res; 1991 May; 51(10):2593-8. PubMed ID: 1673637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
    Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
    Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.